Modality
Vaccine
MOA
JAK1/2i
Target
PI3Kα
Pathway
Incretin
HCC
Development Pipeline
Preclinical
~Feb 2018
→ ~May 2019
Phase 1
~Aug 2019
→ ~Nov 2020
Phase 2
~Feb 2021
→ ~May 2022
Phase 3
~Aug 2022
→ ~Nov 2023
NDA/BLA
~Feb 2024
→ ~May 2025
Approved
Aug 2025
→ Jan 2030
ApprovedCurrent
NCT03124065
2,102 pts·HCC
2025-08→2030-01·Not yet recruiting
2,102 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2030-01-093.8y awayPh3 Readout· HCC
Trial Timeline
Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030
Approved
Not yet…
Catalysts
Ph3 Readout
2030-01-09 · 3.8y away
HCC
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03124065 | Approved | HCC | Not yet recr... | 2102 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Niramavacamten | Hansoh Pharma | Phase 2 | SGLT2 |